In 2025 this was a one-product market. Pfizer markets the innovator brand Elicuis in Mexico and Bristol-Myers Squibb co-owns the molecule and the Eliquis franchise, and between them they held effectively the entire MXN 5,676.0 million. There was no meaningful price competition because there was no competing product, and the clinical argument for apixabán over warfarin was strong enough that demand did not need to be bought.
By 2026 the market had three tiers. The innovator holds the top at MXN 2,205 for 60 tablets. A branded non-innovator, Exbuten, sits in the middle at MXN 1,222 and takes 44.6 per cent off without being a generic at all. The bottom tier is generic apixabán, and its deepest price is a pharmacy private label at MXN 598. Nine suppliers hold meaningful share or a live registration, which makes the structure moderately consolidated on paper; at the counter the intensity is high and the competitive variable is price alone.
Nothing else can be competed on. Bioequivalence is a regulatory threshold, so no entrant can claim superior efficacy. The molecule is a tablet, so no entrant can claim a delivery advantage. The only remaining axes are pack size, listing breadth and price, and pack size is a merchandising decision rather than a clinical one: the same molecule is sold in 20, 30, 60 and 100 tablet boxes, which converts a chronic therapy into a choice about how much cash a patient can put down at one time.
The named generic presence includes Weser Pharma, whose Prasucor apixabán reaches the market through online pharmacy channels, Avivia, whose 20-tablet generic lists at MXN 259, and Productos Farmacéuticos, which filed a new apixabán registration application in the April 2026 COFEPRIS batch. The April 2026 batch also carried a rivaroxabán application from Weser, which matters for substitution risk: the two leading factor Xa inhibitors will reach commodity pricing in the same window, and a prescriber who switches on price will have two generic options rather than one.
The competitive position that is genuinely defensible in this market is the chain. A banner with 3,084 counters and a private label controls both the listing decision and the price, and it does so without owning a patent or a factory. That is a weaker moat than a molecule patent and a much stronger one than a brand.
" value_chain_content: "The apixabán chain has four links and Mexico controls two of them. The active pharmaceutical ingredient is synthesised outside Mexico and imported; the finished tablet is formulated and packaged, largely by Mexican plants operating for generics houses or for the chains themselves; distribution runs through a small number of national distributors into concentrated pharmacy chains; and dispensing happens at more than 17,800 counters across six banners, or inside a public hospital formulary.
The margin sits in the link that is scarcest, and after 2026 that is no longer the laboratory. On the innovator product the value chain was inverted: the molecule patent was the barrier, so the margin accrued at the top of the chain and everyone below it took a distribution spread. Once the substance patent is exhausted and bioequivalence is a regulatory threshold rather than a technical achievement, the tablet becomes a commodity and the barrier moves to the shelf. That is why the deep price cut in Mexico came from a chain private label at MXN 598 rather than from a generics house undercutting the innovator directly.
For a generic entrant the two costs that decide whether the business works are the API contract and the listing fee. The API is the larger of the two and the one the entrant does not control, because apixabán is a single-source molecule synthesised by a small group of Indian and Chinese manufacturers, and the price of the input is set in that market rather than in Mexico. A manufacturer who buys apixabán API at a favourable contract and places it with a Mexican formulation plant has a business at MXN 598 a box. One who buys at spot does not. The global active pharmaceutical ingredient market sets that input price, and the relationship between what an API costs and what a finished tablet earns is what separates a viable generic entrant from a launch that quietly stops being supplied.
The second structural feature is that the chain and the manufacturer can be the same economic actor. When Farmacias Benavides sells apixabán under a Genérico de Marca label with the manufacturer field on its own product record reading Marca Propia, the retail margin and the manufacturing margin are captured together and the wholesale spread that would have gone to a third-party laboratory stays inside the chain. Across more than 17,800 counters, that is a value-chain position no independent generics house can match on price.
" investment_activity_content: "Capital in this market is flowing to formulation, listing and channel, and almost none of it to molecule discovery, which is the correct allocation for a mature off-patent cardiovascular agent. The investment question an entrant actually faces is not whether apixabán works, it is how much shelf it can buy and at what API cost.
Three forms of capital are being deployed. The first is formulation and capacity: converting apixabán API into finished tablets at a Mexican plant, either owned or contracted. Capital intensity is medium rather than high, because the process is standard tableting and does not require the containment or bioreactor capacity that a high-potency or biologic product would. The second is regulatory: dossier preparation, bioequivalence studies and the litigation defence that the linkage system makes unavoidable, which is a recurring cost rather than a one-off and is the cost the patent system was designed to impose. The third is trade: listing fees, promotional support and pack-size investment to get onto the shelf of a banner with 3,000 counters.
The return profile is unattractive at the top of the market and attractive in the middle. An innovator defending MXN 2,205 against a MXN 598 private label is investing to slow a decline that is already in the arithmetic. A generics house with a favourable API contract and a national listing is investing into a patient base growing at 7.38 per cent a year. A chain with a private label is investing into the only position in the chain that controls both the listing and the price, which is why the private-label tier is where the launch actually happened.
The investment that is not happening is the one that would close the institutional half. Until the amparo is resolved, capital aimed at the public tender is capital aimed at a door that does not open, and the 40.0 per cent of patient-years sitting behind that door stays priced as though the patent were alive. The global prescription drugs market sets out how reference pricing and reimbursement structures convert a list price into a reimbursed price, which is the mechanism that will decide what happens to this market on the day the tender reopens.
Recent merger and acquisition activity in the Mexican apixaban market is nil. The consolidation that matters happened earlier and further up: the molecule is owned by a two-company partnership and the channel is owned by six banners, and neither needs to buy anything to hold its position.
" technology_innovation_content: "There is no innovation left in the molecule. Apixabán is a direct factor Xa inhibitor approved more than a decade ago, dosed twice daily, delivered as an immediate-release tablet, and its therapeutic profile has not changed. Innovation intensity in this market is low and technology maturity is at the end of its curve, which is exactly the condition that makes a market a price market.
The innovation that is happening is in the channel, and it is the reason a generics launch reaches national scale in a single quarter. Three systems carry it. Electronic prescribing makes the active substance the ordering variable rather than the brand, so a prescriber selecting apixabán rather than Elicuis hands the substitution decision to the counter. Chain inventory and replenishment systems let a banner move a private label into more than a thousand stores on a single instruction, which is a distribution capability that did not exist at this scale a decade ago. And the COFEPRIS Visor de Registros Sanitarios, live since 22 April 2026, makes registration status machine-readable across 28 fields, which turns what used to be a documentary exercise into a lookup.
Substitution technology is the other live frontier, and it is regulatory rather than digital. The Genérico Intercambiable mark is the only official signal that a product passed the bioequivalence tests, and the September 2025 amendment to the interchangeability criteria governs how that mark is earned. In a market where a MXN 598 box and a MXN 2,205 box sit on the same shelf with the same molecule name, the mark is doing work that the price cannot: it is the only thing telling a patient that the cheaper box is the same medicine.
Where technology could change the forecast is adherence. A twice-daily oral anticoagulant with no monitoring requirement is already the low-friction option against warfarin, but a chronic therapy still depends on refill behaviour, and 60-tablet packaging aligns a refill with a month. Nothing currently in the Mexican market addresses adherence with a technology that would move volume beyond the coverage assumptions used here, and no such product is in late-stage development for this molecule.
" market_risk_content: "The dominant risk in this market is legal rather than commercial, and it runs in both directions. If the innovator amparo that blocks generic participation in public procurement is lifted, the institutional channel reprices toward the retail price and the value line falls considerably faster than forecast. If it is upheld and extended, the institutional channel stays at innovator pricing and this market holds roughly MXN 1.5 billion a year of value that the retail channel has already lost. That single variable moves more revenue than any assumption about patient numbers, and it is the reason the scenario range on this market is wide.
The second risk is a price war below the current generic rung. MXN 598 for 60 tablets is the deepest observed price, not a floor. A second chain private label, or a generics house willing to buy share, could take the generic tier down further, and because 74 per cent of 2033 patient-years are generic, each MXN 100 off the monthly price removes roughly MXN 370 million of annual revenue at 2033 volumes. The market has no non-price defence available to it.
Substitution risk is high and rising. Rivaroxabán generic applications were in the same April 2026 COFEPRIS batch as apixabán, and a prescriber choosing between two commodity factor Xa inhibitors has no clinical reason to prefer either. Apixabán holds 30 per cent of oral anticoagulation in the base year and the forecast takes it to 38 per cent, which assumes it wins share from warfarin faster than it loses share to rivaroxabán. If the two split the direct oral anticoagulant class evenly, the volume path in this report is not reached and the revenue decline is steeper.
Quality and counterfeiting risk is material and is not hypothetical. A falsified and irregularly marketed batch of Elicuis was the subject of a public health alert issued through the Baja California Sur state health risk agency. A market where the same molecule trades at MXN 598 and MXN 2,205 creates a counterfeiting incentive proportional to the spread, and the spread is currently 72.9 per cent.
Currency risk sits underneath all of it. This report holds the peso at MXN 18.7005 to the dollar, the Banco de Mexico rate published in the Diario Oficial on 23 October 2026. The API is imported and the finished product is priced in pesos, so a weaker peso compresses the generic entrant's margin at exactly the moment the entrant has committed to a fixed shelf price, and the peso has been the weaker side of the carry trade through the second half of 2026.
Overall market risk is high. Geopolitical exposure is moderate, because the supply chain is concentrated in a small number of API producers in two countries but the molecule itself is not a strategic good. Substitution risk is high, regulatory complexity is high, and competitive intensity at the counter is high. The one thing this market is not is uncertain about direction: the price has moved, and it does not move back.
" regulatory_landscape_content: "Two agencies govern entry and they do not answer the same question. COFEPRIS decides whether a product is safe and interchangeable. IMPI decides whether a patent stands in the way. The linkage between them is where apixabán has spent its post-patent life.
The mechanism works like this. When a Mexican laboratory applies for a generic registration, COFEPRIS must confirm with IMPI that the innovator patent has ended. IMPI returns lists of live patents, and where the position is unclear COFEPRIS declines the application, even though the only exclusivity the law protects for twenty years is the one covering the active substance. Secondary patents on formulation, use, dosing and pharmaceutical form then provide the grounds for further litigation. The legal adviser to AMELAF, the Mexican pharmaceutical laboratory association, put the share of cases in which a generic fails to reach the market the day after expiry at up to 90 per cent, attributing it to the volume of legal recourse rather than to any gap in the statute.
Apixabán is a live instance. In April 2026 the director general of IMPI named it publicly as a parallel to the denosumab litigation that revived an expired patent, and described active disputes at IMPI, at the collegiate courts and possibly at the Supreme Court. The operative fact for this market is narrower than the litigation: generic companies hold sanitary registration and have won their cases, and a further amparo from the innovator keeps their participation in public procurement blocked. Retail is unaffected because retail does not run through the tender.
The surrounding rules are stable and, on their own terms, workable. The Bolar clause in the Reglamento de Insumos para la Salud gives generic manufacturers three years before innovator registration expiry, and eight years for biotechnological products, to conduct development work. The Consejo de Salubridad General amended the criteria for demonstrating interchangeability in an agreement published in the Diario Oficial on 26 September 2025, which is the test a product must pass to carry the Genérico Intercambiable mark. And since 22 April 2026 COFEPRIS has operated a public Visor de Registros Sanitarios de Medicamentos carrying 28 fields per registration, including registration number, brand, holder, manufacturer, status and distributors, searchable on eight criteria and exportable, which replaces the previous consultation mechanism and makes the registration position of any apixabán brand checkable rather than asserted.
The regulatory complexity of this market is high and it is procedural rather than technical. The tablet is easy. The dossier, the linkage and the injunction are not.
" faq_question_1: Why is generic apixaban cheaper in Mexican pharmacies than in public hospitals faq_answer_1: "Because the two halves of the Mexican apixaban market transact through different gates. Retail is unblocked, so a chain private label reached MXN 598 for 60 tablets in 2026 and a patient paying cash gets that price. Public procurement is blocked: several generic manufacturers hold COFEPRIS sanitary registration for apixabán and have won court rulings, but a further amparo from the innovator keeps their participation in tenders blocked, as IMPI and trade reporting set out in 2026. The institutional channel therefore still transacts at innovator pricing. Pheonix Research measures MXN 28,800 per patient-year at retail against MXN 16,800 institutional in 2025, but the direction of the gap is what matters: the institutional price has not yet fallen to the generic rung." faq_question_2: How large is the apixaban market in Mexico faq_answer_2: "Pheonix Research sizes it at MXN 5,676.0 million, or USD 303.5 million, in 2025 across 236,500 patient-years of therapy, and at MXN 4,359.7 million, or USD 233.1 million, in 2033 across 418,000 patient-years. Volume compounds at 7.38 per cent a year across the eight years and revenue compounds down at 3.24 per cent, because revenue per patient-year falls from MXN 24,000 to MXN 10,430 once generic product holds 74 per cent of treated patients." faq_question_3: What does generic apixaban cost in Mexico faq_answer_3: "The deepest observed shelf price in 2026 is MXN 598 for a 60-tablet box of apixabán 5 mg under a pharmacy chain private label, which is one month of twice-daily therapy and MXN 7,176 for a patient-year. An independent generic label sells a 20-tablet box at MXN 259, roughly MXN 9,324 a patient-year. A branded non-innovator, Exbuten, lists at MXN 1,222 for 60 tablets or MXN 14,664 a patient-year. The innovator brand Elicuis lists at MXN 2,205 for 60 tablets, which is MXN 26,460 a patient-year, so the generic price is 72.9 per cent below the innovator on the same shelf." faq_question_4: How many people in Mexico are treated with apixaban faq_answer_4: "The joint Mexican position document on atrial fibrillation estimates 1.50 million people with the condition in Mexico. At 46 per cent anticoagulation coverage that is 690,000 anticoagulated patients, and at a 30 per cent apixabán share of oral anticoagulation that is 207,000 atrial-fibrillation patient-years. Adding 29,500 patient-years from venous thromboembolism treatment, recurrence prevention and post-orthopaedic prophylaxis gives the 236,500 patient-years of therapy that this report uses as its 2025 base." global_schema: organization: "@id": MIWS-root#organization "@type": Organization url: "https://www.pheonixresearch.com/" name: Pheonix Research website: "@id": MIWS-root "@type": WebSite url: "https://www.pheonixresearch.com/" name: Pheonix Research api: "@id": MIWS-root#api "@type": WebAPI url: "https://www.pheonixresearch.com/" graph: node_id: MIMR-node_ff7fc41 graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIMR-node_ff7fc41" graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph" graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions" graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta" graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle" discovery: discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json" llms_txt: "https://www.pheonixresearch.com/llms.txt" sitemap: "https://www.pheonixresearch.com/sitemap.xml" --- # Mexico Apixaban Market Size, Share and Forecast 2026–2033: The Molecule Treats 77 Per Cent More Patients and Earns 23 Per Cent Less - **Market Size (Base Year):** USD 303.52 Million - **Forecast Value:** USD 233.13 Million - **CAGR:** -3.24% - **Forecast Period:** 2026 - 2033 - **Coverage:** Country - Mexico ## Executive Summary The Mexican apixaban market was worth MXN 5,676.0 million, or USD 303.5 million, in 2025 across 236,500 patient-years of therapy. Generic apixabán arrived on chain-pharmacy shelves in 2026 at MXN 598 for a 60-tablet box, one month of therapy, against MXN 2,205 for the innovator brand Elicuis on the same shelf. That is 72.9 per cent off and it is the first price movement the molecule has seen in Mexico. Pheonix Research forecasts the market at MXN 4,359.7 million, or USD 233.1 million, in 2033 across 418,000 patient-years. Volume compounds at 7.38 per cent a year and revenue compounds down at 3.24 per cent across the eight years, because revenue per patient-year falls from MXN 24,000 to MXN 10,430. The market separates in two. Retail carries 141,900 patient-years at MXN 28,800 and the institutional channel carries 94,600 at MXN 16,800; generic manufacturers hold registrations and have won court rulings, but an innovator amparo keeps them out of public procurement. The counter is open and the tender is not, and the arbitrage between the two is worth MXN 1,589.3 million a year. ## Market Report ## Mexico Apixaban Market Overview Generic apixabán reached the shelves of Mexico's pharmacy chains in 2026, and the price it arrived at is the whole story. A 60-tablet box of apixabán 5 mg, which is one month of twice-daily therapy, now lists at **MXN 598** under a chain's own private label. The innovator product on the same shelf, Elicuis, lists at **MXN 2,205**. That is 72.9 per cent off, and it is the first time the price of this molecule has moved in Mexico since it was launched. The consequence is arithmetic rather than opinion. Pheonix Research puts the Mexican apixaban market at **MXN 5,676.0 million, or USD 303.5 million, in 2025**, across 236,500 patient-years of therapy. By 2033 the same market treats **418,000 patient-years**, which is 76.7 per cent more people, and turns over **MXN 4,359.7 million, or USD 233.1 million**, which is 23.2 per cent less money. Patient-years compound up at 7.4 per cent a year for eight years; revenue compounds down at 3.2 per cent over the same eight years. The molecule wins and the revenue line loses, and both of those are true at once. What makes Mexico distinct from every other market where apixabán has gone generic is that the two halves of the market have separated. The counter is open. The tender is not. Generic registrations exist, generic product is on chain-pharmacy shelves, and generic manufacturers have won court rulings, yet a further *amparo* from the innovator keeps those same manufacturers out of public procurement, which is the channel where 40 per cent of the volume sits. A patient paying cash at a Guadalajara counter gets the new price. IMSS does not. **Companion analysis.** Why the two channels in this market pay different prices for the same molecule, and what closes the gap, is examined in [The Generic Is on the Shelf, Not in the Tender](https://www.pheonixresearch.com/pharmaceutical/pharmaceuticals/article/the-generic-is-on-the-shelf-not-in-the-tender/); the headline findings are announced in the [press release](https://www.pheonixresearch.com/pharmaceutical/pharmaceuticals/press-release/mexico-apixaban-market-reaches-mxn-5676-0-million-in-2025-as-generic-entry-cuts-the-shelf-price-72-9-per-cent-pheonix-research/). ## Market Forecast Snapshot | Indicator | | Value | | Market value, 2025 | | MXN 5,676.0 million (USD 303.5 million) | | Market value, 2033 | | MXN 4,359.7 million (USD 233.1 million) | | Value CAGR, 2025 to 2033, eight years | | −3.24 per cent | | Volume, 2025 | | 236,500 patient-years | | Volume, 2033 | | 418,000 patient-years | | Volume CAGR, 2025 to 2033, eight years | | +7.38 per cent | | Revenue per patient-year, 2025 | | MXN 24,000 | | Revenue per patient-year, 2033 | | MXN 10,430 | | Generic share of patient-years, 2033 | | 74 per cent | | Largest channel, 2025 | | Retail pharmacy chains, 60.0 per cent of patient-years and 72.0 per cent of value | | Base year / forecast year | | 2025 / 2033 | | Currency basis | | USD per MXN 18.7005, Banco de Mexico rate of 22 October 2026, published in the Diario Oficial on 23 October 2026 | Values are transaction value at the point of sale. For the retail channel that is the shelf price including VAT and pharmacy margin; for the institutional channel it is the awarded unit price. This is the basis on which a patient and a payer actually transact, and it is the right basis for a market whose central event is a price. ## Year-by-Year Market Growth Projections | Year | | Patient-years | | Revenue, MXN million | | Revenue per patient-year, MXN | | Generic share of patient-years | | 2025 | | 236,500 | | 5,676.0 | | 24,000 | | 0 per cent | | 2026 | | 255,500 | | 5,212.2 | | 20,400 | | 18 per cent | | 2027 | | 277,000 | | 4,916.8 | | 17,750 | | 31 per cent | | 2028 | | 300,500 | | 4,660.8 | | 15,510 | | 43 per cent | | 2029 | | 325,000 | | 4,475.3 | | 13,770 | | 53 per cent | | 2030 | | 349,500 | | 4,351.3 | | 12,450 | | 61 per cent | | 2031 | | 373,000 | | 4,293.2 | | 11,510 | | 67 per cent | | 2032 | | 395,500 | | 4,311.0 | | 10,900 | | 71 per cent | | 2033 | | 418,000 | | 4,359.7 | | 10,430 | | 74 per cent | The floor of the revenue line is 2031, at MXN 4,293.2 million. Revenue turns back up in 2032 and 2033 not because price recovers but because volume growth finally outruns the price decline. By then the market is earning MXN 4,000 less per patient-year than it did in 2025, and it is treating 181,500 more of them. ## The Price Ladder That Arrived in 2026 Apixabán is dosed at 5 mg twice daily, so a 60-tablet box is a month and twelve boxes are a patient-year. That makes the shelf a directly readable annual price, which is rare in pharmaceuticals and is the reason this market can be measured from retail listings rather than from a modelled average. | Product on the Mexican shelf | | Box, 60 tablets | | Patient-year, 12 boxes | | Against the innovator | | Generic apixabán, chain private label (Farmacias Benavides "Genérico de Marca") | | MXN 598 | | MXN 7,176 | | −72.9 per cent | | Generic apixabán, independent label (Avivia, 20-tablet box) | | MXN 259 per 20 tablets, MXN 777 monthly equivalent | | MXN 9,324 | | −64.8 per cent | | Second brand (Exbuten) | | MXN 1,222 | | MXN 14,664 | | −44.6 per cent | | Innovator (Elicuis, Pfizer) | | MXN 2,205 | | MXN 26,460 | | — | Three rungs, not two. The interesting rung is the middle one: a branded non-innovator sits at MXN 1,222 and takes 44.6 per cent off without being a generic at all. The price umbrella was not broken by a generics house attacking the innovator. It was broken twice, once by a second brand and once by the chain's own label, and the deeper cut came from the pharmacy rather than from a laboratory. That ordering matters for who captures the value. When a chain sells its own private-label apixabán at MXN 598, the retail margin and the manufacturing margin sit on the same income statement. The party that owns the counter owns the price, and in Mexico six chains own most of the counters. ## Why Volume Grows While Revenue Falls The treated population, not the price, is the binding constraint on this market. The joint Mexican position document on atrial fibrillation, the national clinical consensus, puts more than 1.50 million Mexicans with the condition and describes anticoagulation uptake in Mexico as persistently below the levels seen in comparable health systems. The private-cardiology evidence points the same way: in a cross-sectional study of 337 confirmed cases across three cardiology practices in northeast Mexico, only 31.9 per cent of patients with a CHA2DS2-VASc score of two or more were on any oral anticoagulant, and 53.3 per cent of those were on a novel oral anticoagulant rather than a vitamin K antagonist. A price that falls by 72.9 per cent does not create patients. It moves patients who were already diagnosed onto therapy, and it moves patients who were on warfarin onto a direct factor Xa inhibitor that needs no INR monitoring and no dietary discipline. That is where the 76.7 per cent volume growth comes from: not from a larger disease population, but from closing the gap between the people who have atrial fibrillation and the people who are treated for it. The statin market is the template for this curve, and it ran it a decade and a half earlier. [The global statin market](https://www.pheonixresearch.com/pharmaceutical/pharmaceuticals/market-report/global-statin-market/) is what a cardiovascular molecule looks like after the patent has gone: volume is set by the size of the eligible population and the price is set by whoever is cheapest on the shelf, and the two stop moving together. Apixabán is on the same curve. The difference is the litigation tail, which the statins never had, and which is why half of this market is still priced as though the patent were alive. ## The Counter Is Open and the Tender Is Not In April 2026 the head of Mexico's patent institute described the apixabán situation in public. Santiago Nieto Castillo, director general of the Instituto Mexicano de la Propiedad Industrial, named apixabán as a parallel case to the denosumab litigation that had revived an expired patent, and said there were active disputes at IMPI, at the collegiate courts and possibly at the Supreme Court. The reporting around that interview states the outcome plainly: several generic companies hold sanitary registration for apixabán and have won their cases, and a new *amparo* from the innovator keeps their participation in public procurement blocked. This is not an unusual mechanism in Mexico, it is the standard one. The legal adviser to AMELAF, the association of Mexican pharmaceutical laboratories, described the linkage system in 2024: when a national laboratory applies for a registration, COFEPRIS must confirm with IMPI that the innovator patent has ended, IMPI returns lists of dozens of live patents, and faced with the doubt COFEPRIS declines the application even though the only exclusivity the law protects for twenty years is the one on the active substance. He put the share of cases where generics fail to reach the market the day after expiry at up to 90 per cent. The result is a market with two prices running in parallel for the same molecule, in the same country, in the same year. The retail channel has cleared at the generic price. The institutional channel has not. Since the institutional channel carries 40.0 per cent of patient-years and 28.0 per cent of value in 2025, the arbitrage is worth roughly MXN 1,589.3 million a year, and it is the single largest number in this report. There is one more consequence, and it is a safety one. A falsified and irregularly marketed batch of Elicuis was subject to a public health alert issued through the Baja California Sur state health risk agency, which is what happens when one version of a molecule costs four times another and the packaging is the only thing distinguishing them. Price dispersion at this scale creates a counterfeiting incentive that a single price does not. ## Market Segmentation The market splits first by channel, and the channel split is where the forecast does its work. | Channel | | 2025 patient-years | | 2025 revenue, MXN million | | 2033 patient-years | | 2033 revenue, MXN million | | Retail pharmacy, chains and independents, cash and private insurance | | 141,900 | | 4,086.7 | | 263,340 | | 2,844.1 | | Institutional and public procurement, IMSS, ISSSTE, state systems, hospitals | | 94,600 | | 1,589.3 | | 154,660 | | 1,515.7 | | **Total** | | **236,500** | | **5,676.0** | | **418,000** | | **4,359.7** | Read the two revenue cells in the retail row against each other. Retail revenue falls 30.4 per cent while retail patient-years rise 85.6 per cent. That is what a price premium collapsing looks like. In 2025 a retail patient-year was worth MXN 28,800 against MXN 16,800 institutional, a ratio of 1.71. By 2033 the same ratio is 1.10, MXN 10,800 against MXN 9,800. The generic wave does not merely cut the retail price, it destroys the reason the retail price was higher, which is that the innovator had no competition and the tender had no alternative. By product status, 2025 is a single-product market: the innovator holds effectively 100 per cent of patient-years and the entire MXN 5,676.0 million. By 2033 the generic share of patient-years is 74 per cent and the generic share of value is 51 per cent, because the residual innovator volume carries a price that is still three times the generic one. By indication, 87.5 per cent of 2025 patient-years are atrial fibrillation stroke prevention and 12.5 per cent are venous thromboembolism treatment and recurrence prevention plus post-orthopaedic prophylaxis; the non-atrial-fibrillation share rises to 13.0 per cent by 2033 as day-surgery volumes grow. ## Competitive Snapshot The molecule is supplied in Mexico by **Pfizer**, which markets the innovator brand Elicuis, and **Bristol-Myers Squibb**, which co-owns apixabán and the Eliquis franchise globally; the two companies developed and commercialise the molecule jointly, and the Mexican registration sits with the innovator side of that partnership. Against them stands a group of Mexican and Indian generics manufacturers, several of which already hold sanitary registration and have litigated successfully, plus the pharmacy chains themselves operating private labels. The generic entrants visible on Mexican shelves or in the COFEPRIS application lists include **Weser Pharma**, whose Prasucor apixabán is sold through online pharmacy channels, **Avivia**, whose 20-tablet generic is listed at MXN 259, and **Productos Farmacéuticos**, which filed a new apixabán registration application in the April 2026 COFEPRIS batch. The single most consequential entrant is not a laboratory at all: **Farmacias Benavides** sells apixabán 5 mg under a "Genérico de Marca" private label at MXN 598 for 60 tablets, with the manufacturer field on its own product record reading "Marca Propia". Nine suppliers hold meaningful share or a live registration. The structure is moderately consolidated on paper and highly competitive at the counter, and the competitive intensity is concentrated in a single variable: price. There is no efficacy argument to make, because bioequivalence is a regulatory threshold rather than a marketing claim, and there is no formulation argument to make, because the molecule is a tablet. Everything that can be competed on is competed on price. ## The Channel: Six Chains, More Than 17,800 Counters Mexico's pharmacy retail is one of the most concentrated in Latin America, and the concentration is the reason a generics launch reaches national scale in a single quarter. | Chain | | Counters, latest cut | | 2024 sales, MXN million | | Sales per counter, MXN million | | Farmacias Similares (Dr. Simi) | | about 10,000, Mexico and Chile, December 2025 | | not published | | — | | Farmacias Guadalajara | | 3,084, second quarter 2026 | | 120,238 | | 39.0 | | Farmacias del Ahorro | | about 2,000, August 2026 | | 61,538 | | 30.8 | | FEMSA Division Salud, YZA, Moderna, Farmacon | | more than 1,500 across 17 states | | 79,755 | | 53.2 | | Farmacias Benavides | | more than 1,100 across 190 cities and 22 states | | 17,646.5 | | 16.0 | | Farmacias San Pablo | | more than 150 across 8 states | | not published | | — | More than 17,800 counters sit across those six banners. A molecule that reaches all six is nationally distributed without a single hospital contract, which is precisely what has happened to apixabán. The private-label economics explain the speed: a chain that sells its own label at MXN 598 keeps the wholesale spread it used to hand to a laboratory, so the incentive to switch the shelf is the chain's own margin rather than a manufacturer's promotional budget. This is the structure that took generics to seven of every ten medicines sold in Mexico, a share the manufacturers themselves now describe as saturation, with growth slowing to 8 or 9 per cent between 2023 and 2025. Apixabán is not an exception to that pattern, it is the newest and highest-value instance of it. For the wider mechanics of how that share was built, and why a market at seven-in-ten is still growing in value, [the global generic drug market](https://www.pheonixresearch.com/healthcare/healthcare-pharmaceuticals/market-report/global-generic-drug-market/) sets out the substitution economics that the Mexican chains have already industrialised. ## How the Figures Were Built The unit of this market is the patient-year, because it is the only unit that stays constant while the price moves. One patient-year is one person on apixabán for twelve months at the standard 5 mg twice-daily dose, which is twelve 60-tablet boxes. The base is built from the national clinical estimate. The joint Mexican position document on atrial fibrillation puts 1.50 million Mexicans with the condition. Anticoagulation reaches 46 per cent of them, which produces 690,000 anticoagulated patients, and apixabán holds 30 per cent of oral anticoagulation across four direct oral anticoagulants plus warfarin, which produces 207,000 patient-years in atrial fibrillation. A further 29,500 patient-years come from venous thromboembolism treatment and recurrence prevention and from post-orthopaedic prophylaxis, taking the 2025 base to 236,500 patient-years. That base is then priced channel by channel rather than at a national average, because the two channels transact at genuinely different prices. Retail carries 141,900 patient-years at MXN 28,800, which is MXN 4,086.7 million and is read directly off the shelf: twelve boxes of the innovator product at the chain list price of MXN 2,205. Institutional carries 94,600 patient-years at MXN 16,800, which is MXN 1,589.3 million and reflects awarded tender pricing rather than list. The two together give 236,500 patient-years and MXN 5,676.0 million, or MXN 24,000 blended per patient-year. To 2033 the patient base grows on three drivers that are each observable. The atrial fibrillation population rises from 1.50 million to 1.65 million on ageing alone. Anticoagulation coverage rises from 46 to 58 per cent as a cheaper molecule removes the cost objection that suppressed treatment. Apixabán share of oral anticoagulation rises from 30 to 38 per cent as warfarin continues to lose ground to unmonitored therapy. Those three give 363,660 atrial-fibrillation patient-years, and non-atrial-fibrillation use adds 54,340, for 418,000 patient-years. Pricing to 2033 runs on the observed generic ladder rather than on an assumed erosion rate. The generic rung is held at MXN 7,176 a patient-year, which is the current chain private-label price and is the level at which the molecule has cleared. The branded rung declines from MXN 23,300 to MXN 19,700 as the innovator defends share with discounts rather than with list-price cuts. The blend of the two, weighted by a generic share that rises from 18 per cent in 2026 to 74 per cent in 2033, produces revenue per patient-year of MXN 20,400 in 2026 falling to MXN 10,430 in 2033. Multiplied through the patient-year path that gives MXN 5,212.2 million in 2026 and MXN 4,359.7 million in 2033. Currency is held throughout at the Banco de Mexico rate of MXN 18.7005 to the dollar published in the Diario Oficial on 23 October 2026, which puts the 2025 market at USD 303.5 million and the 2033 market at USD 233.1 million. ## Companion Analysis The price argument in this report sits inside a wider set of questions about what a molecule is worth once it is no longer exclusive. [The global prescription drugs market](https://www.pheonixresearch.com/pharmaceutical/pharmaceuticals/market-report/global-prescription-drugs-market/) carries the reference-pricing and reimbursement structures that decide whether a Mexican list price is a real price or an opening bid. [The global active pharmaceutical ingredient market](https://www.pheonixresearch.com/pharmaceutical/pharmaceuticals/market-report/global-active-pharmaceutical-ingredient-api-market/) carries the other half of the generic entrant's margin, which is set at the API contract rather than at the pharmacy shelf, and apixabán's API is the one link in this chain that Mexico does not control. ## Table of Contents Table of Contents 1. Market Overview 2. Market Forecast Snapshot 3. Year-by-Year Market Growth Projections 4. The Price Ladder That Arrived in 2026 5. Why Volume Grows While Revenue Falls 6. The Counter Is Open and the Tender Is Not 7. Market Segmentation 8. Competitive Landscape 9. Value Chain 10. Regulatory Landscape 11. Investment Activity 12. Technology and Innovation 13. Market Risk 14. Distribution Channel 15. How the Figures Were Built ## Competitive Landscape Competitive Landscape In 2025 this was a one-product market. Pfizer markets the innovator brand Elicuis in Mexico and Bristol-Myers Squibb co-owns the molecule and the Eliquis franchise, and between them they held effectively the entire MXN 5,676.0 million. There was no meaningful price competition because there was no competing product, and the clinical argument for apixabán over warfarin was strong enough that demand did not need to be bought. By 2026 the market had three tiers. The innovator holds the top at MXN 2,205 for 60 tablets. A branded non-innovator, Exbuten, sits in the middle at MXN 1,222 and takes 44.6 per cent off without being a generic at all. The bottom tier is generic apixabán, and its deepest price is a pharmacy private label at MXN 598. Nine suppliers hold meaningful share or a live registration, which makes the structure moderately consolidated on paper; at the counter the intensity is high and the competitive variable is price alone. Nothing else can be competed on. Bioequivalence is a regulatory threshold, so no entrant can claim superior efficacy. The molecule is a tablet, so no entrant can claim a delivery advantage. The only remaining axes are pack size, listing breadth and price, and pack size is a merchandising decision rather than a clinical one: the same molecule is sold in 20, 30, 60 and 100 tablet boxes, which converts a chronic therapy into a choice about how much cash a patient can put down at one time. The named generic presence includes Weser Pharma, whose Prasucor apixabán reaches the market through online pharmacy channels, Avivia, whose 20-tablet generic lists at MXN 259, and Productos Farmacéuticos, which filed a new apixabán registration application in the April 2026 COFEPRIS batch. The April 2026 batch also carried a rivaroxabán application from Weser, which matters for substitution risk: the two leading factor Xa inhibitors will reach commodity pricing in the same window, and a prescriber who switches on price will have two generic options rather than one. The competitive position that is genuinely defensible in this market is the chain. A banner with 3,084 counters and a private label controls both the listing decision and the price, and it does so without owning a patent or a factory. That is a weaker moat than a molecule patent and a much stronger one than a brand. - **Structure:** moderately_consolidated - **Tier 1 Players:** 9 - **Intensity:** high ## Value Chain Value Chain The apixabán chain has four links and Mexico controls two of them. The active pharmaceutical ingredient is synthesised outside Mexico and imported; the finished tablet is formulated and packaged, largely by Mexican plants operating for generics houses or for the chains themselves; distribution runs through a small number of national distributors into concentrated pharmacy chains; and dispensing happens at more than 17,800 counters across six banners, or inside a public hospital formulary. The margin sits in the link that is scarcest, and after 2026 that is no longer the laboratory. On the innovator product the value chain was inverted: the molecule patent was the barrier, so the margin accrued at the top of the chain and everyone below it took a distribution spread. Once the substance patent is exhausted and bioequivalence is a regulatory threshold rather than a technical achievement, the tablet becomes a commodity and the barrier moves to the shelf. That is why the deep price cut in Mexico came from a chain private label at MXN 598 rather than from a generics house undercutting the innovator directly. For a generic entrant the two costs that decide whether the business works are the API contract and the listing fee. The API is the larger of the two and the one the entrant does not control, because apixabán is a single-source molecule synthesised by a small group of Indian and Chinese manufacturers, and the price of the input is set in that market rather than in Mexico. A manufacturer who buys apixabán API at a favourable contract and places it with a Mexican formulation plant has a business at MXN 598 a box. One who buys at spot does not. The global active pharmaceutical ingredient market sets that input price, and the relationship between what an API costs and what a finished tablet earns is what separates a viable generic entrant from a launch that quietly stops being supplied. The second structural feature is that the chain and the manufacturer can be the same economic actor. When Farmacias Benavides sells apixabán under a Genérico de Marca label with the manufacturer field on its own product record reading Marca Propia, the retail margin and the manufacturing margin are captured together and the wholesale spread that would have gone to a third-party laboratory stays inside the chain. Across more than 17,800 counters, that is a value-chain position no independent generics house can match on price. - **Model:** contract_manufacturing - **Distribution:** retail_chain_dominated - **Supply Complexity:** moderate ## Investment Activity Investment Activity Capital in this market is flowing to formulation, listing and channel, and almost none of it to molecule discovery, which is the correct allocation for a mature off-patent cardiovascular agent. The investment question an entrant actually faces is not whether apixabán works, it is how much shelf it can buy and at what API cost. Three forms of capital are being deployed. The first is formulation and capacity: converting apixabán API into finished tablets at a Mexican plant, either owned or contracted. Capital intensity is medium rather than high, because the process is standard tableting and does not require the containment or bioreactor capacity that a high-potency or biologic product would. The second is regulatory: dossier preparation, bioequivalence studies and the litigation defence that the linkage system makes unavoidable, which is a recurring cost rather than a one-off and is the cost the patent system was designed to impose. The third is trade: listing fees, promotional support and pack-size investment to get onto the shelf of a banner with 3,000 counters. The return profile is unattractive at the top of the market and attractive in the middle. An innovator defending MXN 2,205 against a MXN 598 private label is investing to slow a decline that is already in the arithmetic. A generics house with a favourable API contract and a national listing is investing into a patient base growing at 7.38 per cent a year. A chain with a private label is investing into the only position in the chain that controls both the listing and the price, which is why the private-label tier is where the launch actually happened. The investment that is not happening is the one that would close the institutional half. Until the amparo is resolved, capital aimed at the public tender is capital aimed at a door that does not open, and the 40.0 per cent of patient-years sitting behind that door stays priced as though the patent were alive. The global prescription drugs market sets out how reference pricing and reimbursement structures convert a list price into a reimbursed price, which is the mechanism that will decide what happens to this market on the day the tender reopens. Recent merger and acquisition activity in the Mexican apixaban market is nil. The consolidation that matters happened earlier and further up: the molecule is owned by a two-company partnership and the channel is owned by six banners, and neither needs to buy anything to hold its position. - **Trend:** rising - **Capital Intensity:** medium - **Recent M&A:** no ## Technology & Innovation Technology and Innovation There is no innovation left in the molecule. Apixabán is a direct factor Xa inhibitor approved more than a decade ago, dosed twice daily, delivered as an immediate-release tablet, and its therapeutic profile has not changed. Innovation intensity in this market is low and technology maturity is at the end of its curve, which is exactly the condition that makes a market a price market. The innovation that is happening is in the channel, and it is the reason a generics launch reaches national scale in a single quarter. Three systems carry it. Electronic prescribing makes the active substance the ordering variable rather than the brand, so a prescriber selecting apixabán rather than Elicuis hands the substitution decision to the counter. Chain inventory and replenishment systems let a banner move a private label into more than a thousand stores on a single instruction, which is a distribution capability that did not exist at this scale a decade ago. And the COFEPRIS Visor de Registros Sanitarios, live since 22 April 2026, makes registration status machine-readable across 28 fields, which turns what used to be a documentary exercise into a lookup. Substitution technology is the other live frontier, and it is regulatory rather than digital. The Genérico Intercambiable mark is the only official signal that a product passed the bioequivalence tests, and the September 2025 amendment to the interchangeability criteria governs how that mark is earned. In a market where a MXN 598 box and a MXN 2,205 box sit on the same shelf with the same molecule name, the mark is doing work that the price cannot: it is the only thing telling a patient that the cheaper box is the same medicine. Where technology could change the forecast is adherence. A twice-daily oral anticoagulant with no monitoring requirement is already the low-friction option against warfarin, but a chronic therapy still depends on refill behaviour, and 60-tablet packaging aligns a refill with a month. Nothing currently in the Mexican market addresses adherence with a technology that would move volume beyond the coverage assumptions used here, and no such product is in late-stage development for this molecule. - **Innovation:** low - **Patent Activity:** moderate - **Maturity:** mature ## Market Risk Market Risk The dominant risk in this market is legal rather than commercial, and it runs in both directions. If the innovator amparo that blocks generic participation in public procurement is lifted, the institutional channel reprices toward the retail price and the value line falls considerably faster than forecast. If it is upheld and extended, the institutional channel stays at innovator pricing and this market holds roughly MXN 1.5 billion a year of value that the retail channel has already lost. That single variable moves more revenue than any assumption about patient numbers, and it is the reason the scenario range on this market is wide. The second risk is a price war below the current generic rung. MXN 598 for 60 tablets is the deepest observed price, not a floor. A second chain private label, or a generics house willing to buy share, could take the generic tier down further, and because 74 per cent of 2033 patient-years are generic, each MXN 100 off the monthly price removes roughly MXN 370 million of annual revenue at 2033 volumes. The market has no non-price defence available to it. Substitution risk is high and rising. Rivaroxabán generic applications were in the same April 2026 COFEPRIS batch as apixabán, and a prescriber choosing between two commodity factor Xa inhibitors has no clinical reason to prefer either. Apixabán holds 30 per cent of oral anticoagulation in the base year and the forecast takes it to 38 per cent, which assumes it wins share from warfarin faster than it loses share to rivaroxabán. If the two split the direct oral anticoagulant class evenly, the volume path in this report is not reached and the revenue decline is steeper. Quality and counterfeiting risk is material and is not hypothetical. A falsified and irregularly marketed batch of Elicuis was the subject of a public health alert issued through the Baja California Sur state health risk agency. A market where the same molecule trades at MXN 598 and MXN 2,205 creates a counterfeiting incentive proportional to the spread, and the spread is currently 72.9 per cent. Currency risk sits underneath all of it. This report holds the peso at MXN 18.7005 to the dollar, the Banco de Mexico rate published in the Diario Oficial on 23 October 2026. The API is imported and the finished product is priced in pesos, so a weaker peso compresses the generic entrant’s margin at exactly the moment the entrant has committed to a fixed shelf price, and the peso has been the weaker side of the carry trade through the second half of 2026. Overall market risk is high. Geopolitical exposure is moderate, because the supply chain is concentrated in a small number of API producers in two countries but the molecule itself is not a strategic good. Substitution risk is high, regulatory complexity is high, and competitive intensity at the counter is high. The one thing this market is not is uncertain about direction: the price has moved, and it does not move back. - **Overall Risk:** high - **Geopolitical Exposure:** moderate - **Substitution Risk:** high ## Regulatory Landscape Regulatory Landscape Two agencies govern entry and they do not answer the same question. COFEPRIS decides whether a product is safe and interchangeable. IMPI decides whether a patent stands in the way. The linkage between them is where apixabán has spent its post-patent life. The mechanism works like this. When a Mexican laboratory applies for a generic registration, COFEPRIS must confirm with IMPI that the innovator patent has ended. IMPI returns lists of live patents, and where the position is unclear COFEPRIS declines the application, even though the only exclusivity the law protects for twenty years is the one covering the active substance. Secondary patents on formulation, use, dosing and pharmaceutical form then provide the grounds for further litigation. The legal adviser to AMELAF, the Mexican pharmaceutical laboratory association, put the share of cases in which a generic fails to reach the market the day after expiry at up to 90 per cent, attributing it to the volume of legal recourse rather than to any gap in the statute. Apixabán is a live instance. In April 2026 the director general of IMPI named it publicly as a parallel to the denosumab litigation that revived an expired patent, and described active disputes at IMPI, at the collegiate courts and possibly at the Supreme Court. The operative fact for this market is narrower than the litigation: generic companies hold sanitary registration and have won their cases, and a further amparo from the innovator keeps their participation in public procurement blocked. Retail is unaffected because retail does not run through the tender. The surrounding rules are stable and, on their own terms, workable. The Bolar clause in the Reglamento de Insumos para la Salud gives generic manufacturers three years before innovator registration expiry, and eight years for biotechnological products, to conduct development work. The Consejo de Salubridad General amended the criteria for demonstrating interchangeability in an agreement published in the Diario Oficial on 26 September 2025, which is the test a product must pass to carry the Genérico Intercambiable mark. And since 22 April 2026 COFEPRIS has operated a public Visor de Registros Sanitarios de Medicamentos carrying 28 fields per registration, including registration number, brand, holder, manufacturer, status and distributors, searchable on eight criteria and exportable, which replaces the previous consultation mechanism and makes the registration position of any apixabán brand checkable rather than asserted. The regulatory complexity of this market is high and it is procedural rather than technical. The tablet is easy. The dossier, the linkage and the injunction are not. - **Complexity:** high - **Approval Pathway:** compliance_driven ## Frequently Asked Questions **Q: Why is generic apixaban cheaper in Mexican pharmacies than in public hospitals** Because the two halves of the Mexican apixaban market transact through different gates. Retail is unblocked, so a chain private label reached MXN 598 for 60 tablets in 2026 and a patient paying cash gets that price. Public procurement is blocked: several generic manufacturers hold COFEPRIS sanitary registration for apixabán and have won court rulings, but a further amparo from the innovator keeps their participation in tenders blocked, as IMPI and trade reporting set out in 2026. The institutional channel therefore still transacts at innovator pricing. Pheonix Research measures MXN 28,800 per patient-year at retail against MXN 16,800 institutional in 2025, but the direction of the gap is what matters: the institutional price has not yet fallen to the generic rung. **Q: How large is the apixaban market in Mexico** Pheonix Research sizes it at MXN 5,676.0 million, or USD 303.5 million, in 2025 across 236,500 patient-years of therapy, and at MXN 4,359.7 million, or USD 233.1 million, in 2033 across 418,000 patient-years. Volume compounds at 7.38 per cent a year across the eight years and revenue compounds down at 3.24 per cent, because revenue per patient-year falls from MXN 24,000 to MXN 10,430 once generic product holds 74 per cent of treated patients. **Q: What does generic apixaban cost in Mexico** The deepest observed shelf price in 2026 is MXN 598 for a 60-tablet box of apixabán 5 mg under a pharmacy chain private label, which is one month of twice-daily therapy and MXN 7,176 for a patient-year. An independent generic label sells a 20-tablet box at MXN 259, roughly MXN 9,324 a patient-year. A branded non-innovator, Exbuten, lists at MXN 1,222 for 60 tablets or MXN 14,664 a patient-year. The innovator brand Elicuis lists at MXN 2,205 for 60 tablets, which is MXN 26,460 a patient-year, so the generic price is 72.9 per cent below the innovator on the same shelf. **Q: How many people in Mexico are treated with apixaban** The joint Mexican position document on atrial fibrillation estimates 1.50 million people with the condition in Mexico. At 46 per cent anticoagulation coverage that is 690,000 anticoagulated patients, and at a 30 per cent apixabán share of oral anticoagulation that is 207,000 atrial-fibrillation patient-years. Adding 29,500 patient-years from venous thromboembolism treatment, recurrence prevention and post-orthopaedic prophylaxis gives the 236,500 patient-years of therapy that this report uses as its 2025 base.